T-Detect COVID received the Health Innovation of the Year award by Geekwire and was honored as a finalist in Fast Company’s 2021 World Changing Ideas award in the Pandemic Response category.

T cells know if you had COVID-19.

In studies, T-Detect COVID outperformed antibody tests.1, 2

T cells know if you had COVID-19.

In studies, T-Detect COVID outperformed antibody tests.1, 2

Opt In Email

Be the first to know about T-Detect news, offers and updates.

Sign Up
T Detect Patient Action Home

For Patients

T-Detect COVID can detect past COVID-19 infections for up to several months.

Learn More
T Detect Home Physicans Action

For Physicians

T-Detect COVID can capture past COVID-19 infections that may be missed by serology testing.

Learn More
T Detect Home Employers Action

For Employers

T-Detect COVID can help your employees get the answers they need.

Learn More
T Detect Home Researchers Action

For Researchers

T-Detect COVID can support your research due to its high sensitivity and specificity.

Learn More

About T-Detect

Learn More

Frequently asked questions

How does T-Detect COVID work?

T cells are the first responders of the adaptive immune system and activate the antibody response. While antibodies to SARS-CoV-2 (the virus that causes COVID-19) naturally wane and are detectable in the shorter term, T cell responses can persist in the blood long after antibody responses wane.1,2,4

The T-Detect COVID test can detect T cells in a blood sample that can remain for up to several months after symptoms appear.1,2,3

  1. Zuo J, et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at six months following primary infection. bioRxiv. 2020.
  2. Adaptive data on file.
  3. Ng, O, et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016.
  4. Dalai, S, et al. Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection. medRxiv. 2020.

* T-Detect COVID is not FDA cleared or approved. It is authorized for emergency use under an Emergency Use Authorization.

This test has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA.

Testing of venous whole blood using K2 EDTA specimens is limited to laboratories designated by Adaptive Biotechnologies Corporation that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meets the requirements to perform high complexity tests as described in the T-Detect COVID Test Standard Operating Procedure that was reviewed by the FDA under this EUA.

This test has been authorized only for detecting and identifying the presence of an adaptive T-cell immune response to SARS-CoV-2, not for any other viruses or pathogens.

The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

T-Detect™ COVID is not indicated for use in patients under age 18.

References

  1. Dalai, S, et al. Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection. medRxiv. 2020.
  2. Adaptive data on file.